ALSO NOTED: Wall Street waits on new Pfizer CEO; HGS touts Phase II hep C trial; and much more...

> Wall Street is waiting to see how Jeff Kindler, the new CEO at Pfizer, will handle his role on Thursday as he announces the company's third quarter performance. Analysts want some idea of what new directions he has in mind for Pfizer. Report (WSJ sub. req.)

> Omrix Biopharmaceuticals says that its Phase III non-inferiority study of human thrombin compared to bovine thrombin met its primary endpoints. Both thrombins had similar results in stemming bleeding. Report

> Human Genome Sciences is touting positive data from Phase IIb trials of Albuferon for hepatitis C. Report

> Germany's Evotec will collaborate with Japan's Daiichi for medicinal chemistry and compound profiling. Report

> A Chinese antibiotic maker had its license revoked after an antibiotic it makes was blamed for the death of six people and multiple injuries. Report

> Cambridge Antibody Technology and The Debiopharm Group have entered into an exclusive worldwide licensing agreement to develop and commercialize SC-1. SC-1 is a fully human monoclonal IgM antibody SC-1 that targets CD55SC-1, a cell surface receptor that is specifically expressed on gastric carcinoma cells. Release

> J&J has won a round in federal court in its patent fight against a generic version of Risperdal. A judge has ordered that sales of the generic be held up to the end of 2007. Report

> Hana Biosciences has acquired the rights to develop Menadione, a preclinical therapy intended to prevent skin rash associated with epidermal growth factor receptor inhibitors in certain cancer treatments. Report

> Vical is selling $12.5 million in stock to fund operations. Report

> India's Wanbury will buy the generic drug business of Spain's industrial Farmaceutica Cantabria. Report

And Finally… The U.S. government is creating a new cord blood bank to provide life-saving stem cells needed for therapies. Cord blood contains the same stem cells as bone marrow, but doesn't need the same kind of genetic match to be effective in patients. Article

Suggested Articles

Wedding Five Prime Therapeutics’ cabiralizumab to Bristol-Myers Squibb’s checkpoint inhibitor Opdivo has proved to be a bust in pancreatic cancer.

Sean Harper and Beth Seidenberg tell FierceBiotech how and why they set up their own VC firm, Westlake Village BioPartners.

Imara is looking to cap a good 2019 with an initial public offering in 2020. The rare disease biotech wants $86 million on the Nasdaq.